Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic myeloid leukemia
Pharma
After rejection, FDA accepts Xspray's leukemia med resubmission
With a patent feud settled and its application back at the FDA’s desk, Xspray believes it's on track to launch its first product late this summer.
Fraiser Kansteiner
Feb 12, 2024 10:33am
FDA rejects Xspray's would-be rival to BMS leukemia med Sprycel
Jul 11, 2023 9:55am
Takeda's Iclusig tops Novartis' Gleevec decisively in Ph+ALL
Feb 14, 2023 5:00pm
In Ph+ALL trial, Takeda's Iclusig outdoes Novartis' Gleevec
Nov 17, 2022 10:27am
ASCO: Novartis eyes full nod for Gleevec follow-on Scemblix
May 26, 2022 5:00pm